Fierce Pharma18m
J&J advances Stelara succession scheme with key FDA nod for Tremfya in Crohn's disease
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
Mounjaro hits shelves in India: How Eli Lilly's anti-diabetes drug compares with Ozempic — price, side effects and more
Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration ...
News-Medical.Net2d
Insights into drug absorption and predictive modeling with Professor Kiyohiko Sugano
Learn how drug absorption and predictive modeling drive advancements in pharmaceuticals and precision medicine.
BioSpace2d
AstraZeneca Sets Sights and $1.35B on Subcutaneous Cancer Drugs With Alteogen Alliance
Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.
Endpoints News3d
As­traZeneca taps Al­teogen in deal worth more than $1.3B to make sub­cu­ta­neous can­cer drugs
AstraZeneca is betting roughly $1.35 billion on Korean biotech Alteogen to help develop under-the-skin versions of multiple ...
Contract Pharma3d
AstraZeneca, Alteogen Enter License Agreement for Subcutaneous Formulations of Oncology Assets
To leverage Alteogen's ALT-B4 Hybrozyme platform technology for large volume subcutaneous administration of drugs.
Fierce Pharma3d
AstraZeneca signs Alteogen deal worth up to $1.35B for subcutaneous cancer drugs despite Merck-Halozyme patent drama
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...